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Abstract 
Introduction: Healthcare-associated infections (HAIs) and irrational use of antibiotics in healthcare settings are major global public health 
concerns. Surveillance of HAIs in intensive care units (ICU), surgical-site infections (SSIs), and Clostridium difficile infections (CDIs), together 
with implementation of antibiotic stewardship, are cornerstones of hospital infection prevention programs. The aim of this study was to evaluate 
antibiotic consumption, especially of broad spectrum antibiotics, in relation to HAI incidence density (ID). 
Methodology: The study was conducted from 2011 to 2016 in a tertiary hospital, the Military Medical Academy (MMA), in Belgrade, Serbia. 
Through regular hospital surveillance we identified all patients with a new HAI. Data on consumption of antibacterials for systemic use were 
expressed as defined daily dose per 100 bed days (DDD/100 BD). 
Results: The highest incidence density (ID) of HAI was observed among patients in surgical ICUs (47.2 per 1000 patient-days), while the 
highest incidence rate among SSI was 3.7%. Moreover, the highest ID of CDI in medical patients was 6.2 per 10,000 patient-days, while in 
surgical patients it was 4.3 per 10,000 patient-days. The most frequently used antibiotics were cephalosporins, aminoglycosides and 
carbapenems (16.0 ± 2.3, 4.8 ± 0.7, 4.3 ± 0.7 DDD/100 BD, respectively). There was no significant correlation between consumption of any 
groups of antibiotics and ID of CDI in medical and surgical patients. 
Conclusion: The multidisciplinary healthcare team would have crucial importance in the implementation of the antibiotic stewardship program 
in order to decrease unnecessary exposures of patients treated in healthcare settings. 
 
Key words: Clostridium infections; cephalosporins; carbapenems; surgical site infection. 
 
J Infect Dev Ctries 2018; 12(10):855-863. doi:10.3855/jidc.10827 
 
(Received 03 September 2018 – Accepted 24 September 2018) 
 
Copyright © 2018 Perić et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
 
Introduction 
Healthcare-associated infections (HAIs) and 
irrational use of antibiotic in healthcare settings are 
major global public health concerns [1]. The intensive 
care unit (ICU) is often the epicenter of emerging 
problems of HAIs and antimicrobial resistance in a 
hospital. Patients admitted to ICU are at higher risk of 
HAI due to both intrinsic (age, underlying diseases, 
immunosuppression) and extrinsic (use of invasive 
devices such as mechanical ventilation, central vascular 
catheter,) risk factors (RFs) [2]. A systematic review 
and meta-analysis of the burden of endemic HAI in 
developing countries showed that pooled overall HAI 
infection density in adult ICU was at least three times 
higher than those reported from the US. Strikingly 
higher surgical-site infection (SSIs) rates, the most 
frequent HAI in surgical patients, were also observed in 
developing countries [3]. In contrast, a systematic 
review describing the epidemiology and management 
of Clostridium difficile infection (CDI) in developing 
countries suggested that the rate of community 
associated and healthcare-associated (HA) CDI 
appeared to be lower in developing countries than in 
developed countries, yet RFs appeared to be broadly 
similar between these two populations [4]. Antibiotic 
exposure represents a principal RF for CDI, in both 
developed and developing countries [5,6]. 
Antibiotics are among the most frequently used 
drugs in hospitalized patients. Each antibiotic has a 
different unit dose of daily administration; a specific 
standardized method should be used in the evaluation 
of in-hospital use. The World Health Organization 
Perić et al. – Antibiotics and healthcare-associated infections     J Infect Dev Ctries 2018; 12(10):855-863. 
856 
(WHO) recommends the use of the Anatomical 
Therapeutic Chemical/Defined Daily Dose 
(ATC/DDD) index as a method to express antibiotic 
consumption [7].  
Appropriate antibiotic use in hospitals should 
ensure effective treatment but reduce unnecessary 
prescriptions [8]. Severe infections with multidrug-
resistant pathogens present a medical challenge and a 
financial burden for hospitals. Critically ill patients are 
at very high risk of developing severe HAI in ICU, with 
incidence density (ID) 5-10- fold higher than in general 
medical wards [9,10]. The use of broad spectrum 
antibiotics is a particular problem. Characteristics such 
as the type of healthcare, knowledge of local common 
pathogens and resistance patterns as well as patient RFs 
for colonization or infection with multidrug-resistance 
pathogens should be used to select empirical broad 
spectrum antibiotics [11].  
Surveillance of HAIs in ICU, of SSIs and CDIs 
together with implementation of antibiotic stewardship 
are cornerstones of infection prevention programs in 
modern hospitals. 
The aim of this study was to evaluate the antibiotic 
consumption, especially the broad spectrum ones, and 




This study of the antibiotic consumption and the ID 
of HAIs was conducted over a six-year period (2011-
2016) in the Military Medical Academy (MMA), 
Belgrade, Serbia, a teaching hospital of the University 
of Defence. The MMA is a 1200-bed tertiary healthcare 
centre with 27 departments. The Ethics Committee of 
the MMA approved the research protocol (Project 
MF/VMA/02/17-19). 
The Department of Healthcare-related Infection 
Control performs continuous active surveillance of 
MMA patients since 2006. Through regular hospital 
surveillance of MMA patients we prospectively 
identified all patients who had new HAI during the 
study period. The surveillance of HAI covered patients 
in four type of ICU (medical, surgical, toxicological and 
neurological). The case definitions were those specified 
by the European Centre for Diseases Control (ECDC) 
[2,12]. 
The surveillance of SSIs was conducted among 
general and orthopedic surgery patients, followed by 
surveillance of vascular and cardiac surgery, thoracic 
surgery, plastic surgery and burns, urology and maxillo-
facial surgery patients. The wound class was assigned 
after operative procedure completion based on actual 
occurrences as clean, clean/contaminated, 
contaminated, and dirty/infected [13]. For diagnosis of 
SSI, the CDC criteria were used [14]. 
Patients from all departments were included for the 
surveillance of CDI. A CDI case was defined as any 
hospitalized patient with laboratory confirmation of a 
positive toxin assay or Clostridium difficile nucleic acid 
amplification assay results together with diarrhea (≥ 3 
daily in a 24-hours’ period with no other recognized 
cause) or visualization of pseudomembranes on 
sigmoidoscopy, colonoscopy, or histopathologic 
analysis [15,16]. Microbiological testing was 
performed at the Institute of Medical Microbiology at 
the MMA.  
Only the first episode of HAIs, SSIs and CDIs was 
included for patients who had more than one infection 
during the study period. 
The ID of HAIs in ICU was calculated as the 
number of HAI per 1000 patient-days. The IR of SSI 
was defined as the number of SSIs per 100 operative 
procedures. The ID of CDI was defined as the number 
of HAI CDI caused per 10,000 patient-days in medical 
and surgical patients. 
Drug usage data for antibiotics were obtained from 
the hospital pharmacy records. The number of grams or 
international units of antibiotics were converted into a 
number of DDD using the 2017 version of the 
ATC/DDD index [7]. Data were expressed as DDD per 
100 bed days (DDD/100 BD). DDD is the assumed 
average maintenance adult dose per day for the main 
indication of antibiotic, which refers to ATC code J01 
(antibacterials for systemic use). Antibacterials are 
classified according to their mode of action and 
chemistry. The J01 antibacterials included in this study 
were the following: J01A tetracyclines (J01AA-




amoxicillin/clavulanic acid, piperacillin/tazobactam), 
J01D other beta-lactam antibacterials (J01DB-
cefazolin, J01DC-cefuroxime, J01DD-cefotaxime, 
ceftazidime, ceftriaxone, J01DE-cefepime; J01DH-
carbapenems), J01E sulfonamides and trimethoprim 
(J01EE-sulfametoxazol and trimethoprim), J01F 
macrolides, lincosamides and streptogramines (J01FA-
erythromicyn, azithromycin, J01FF-clindamycin), 
J01G aminoglycoside antibacterials (J01GB-
gentamicin, amikacin), J01M quinolone antibacterials 
(J01MA-ciprofloxacin, levofloxacin), J01X other 
antibacterials (J01XA-vancomycin, teicoplanin, 
J01XB-colistin, J01XD-metronidazole). The 
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prescription of antifungal and antiviral drugs was 
excluded from the study [17]. 
According the patients’ risk of developing CDI, 
antibiotics are grouped as: high risk-antibiotics (ATC 
codes: J01D, J01M and J01FF), medium-risk 
antibiotics (ATC codes: J01C, J01E, J01FA and J01G) 
and a low-risk antibiotics (ATC code: J01A) [5]. 
Relative numbers were expressed as percentages. In 
the case of continuous data, variables were presented as 
a mean value ± standard deviation (SD). Pearson 
correlation analysis was used to establish the 
relationship between different antibiotic groups and ID 
of CDI in medical and surgical patients. Statistical 
significance was set at a level of p<0.05. Complete 
statistical analysis of data was done using SPSS 




The highest ID of HAI was observed in patients in 
surgical ICUs with a peak in 2015 (47.2 per 1000 
patient-days). There was a trend of increasing ID of 
HAIs in the medical and toxicological ICU during the 
study period. The neurological ICU was founded in 
2014; a peak of HAIs was registered in 2015 (23.4 per 
1000 patient-days) (Figure 1). 
From January 1st, 2011 to December 31st, 2016, a 
total of 35,995 different operative procedures were 
evaluated, with an overall cumulative IR of 2.9% 
(1.048) SSIs. 
Among these cases, 22,035 (61.2%) were classified 
as clean, with an IR of 2.0%, 10,499 (29.2%) were 
classified as clean/contaminated with an IR of 3.6%, 
1,866 (5.2%) were classified as contaminated with an 
IR of 5.9%, and 1,595 (4.4%) were classified as 
dirty/infected with an IR of 8.2%. The highest IR was 
registered in 2016 (3.7%) and the lowest in 2011 (2.3%) 
(Figure 2). 
The overall ID of CDIs was highest in 2016 (4.7 per 
10,000 patient-days). The highest ID of CDI among 
medical patients was observed in 2016 (6.2 per 10,000 
patient-days), while in surgical patients it occurred in 
2013 (4.3 per 10,000 patient-days) (Figure 3). 
Figure 1. Incidence density (per 1000 patients-days) of 
Healthcare Associated Infections in surgical Intensive Care 
Units (ICU), medical ICU, toxicological ICU and neurological 
ICU in the Military Medical Academy, 2011-2016. 
Figure 2. Incidence rate (%) of surgical site infection in the 
Military Medical Academy, 2011-2016. 
Figure 3. Incidence density (per 10,000 patient-days) of 
Clostridium difficile infection (CDI) in medical and surgical 
patients in Military Medical Academy, 2011-2016. 
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Antibiotic consumption 
The highest consumption was detected in the years 
2013 and 2015 (46.5 and 46.0 DDD/100 BD, 
respectively) and the lowest consumption in the year 
2016 (33.4 DDD/100 BD). In 2016 there was a decrease 
in consumption of cephalosporins of 25% compared 
with 2015. Overall hospital consumption of antibiotics 
over a six-year period is shown in Table 1. 
The most frequently used antibiotics from 2011 to 
2016 were cephalosporins, followed by 
aminoglycosides and carbapenems (16.0 ± 2.3 
DDD/100 BD, 4.8 ± 0.7 DDD/100 BD and 4.3 ± 0.7 
DDD/100 BD, respectively). The highest consumption 
of cephalosporins was in 2011 (18.6 DDD/100 BD), 
with a rate of 43.5% of total consumption of antibiotics 
in that year, followed by a steady decrease in the 
following years. The lowest consumption was in the 
year 2016 (12.4 DDD/100 BD), at 37.1% of total 
consumption of antibiotics in that year. The trend in 
consumption of aminoglycosides was the same as for 
overall antibiotics consumption. It was highest in 2013 
(5.6 DDD/100 BD), at 12.1% of total consumption of 
antibiotics and lowest in 2016 (4.1 DDD/100 BD) at 
12.4%. Carbapenem consumption was different in 
comparison to the previous two groups. The highest 
consumption was recorded in 2015 (5.0 DDD/100 BD), 
at 11.0% of antibiotic consumption, while the lowest 
consumption was in 2011 (3.1 DDD/100 BD), at 7.3% 
(Figure 4). Meropenem was the mostly commonly used 
carbapenem (average consumption 2.1 ± 0.6 DDD/100 
BD). 
Antibiotics were grouped according to their use for 
patients with different levels of risk of developing CDI: 
high-risk antibiotics (cephalosporins, carbapenems, 
fluoroquinolones and clindamycin), medium-risk 
antibiotics (penicillins, aminoglycosides, macrolides 
and sulfametoxazol/trimethoprim) and low-risk 
antibiotics (tetracycline). The consumption of the three 
groups of antibiotics in DDDs per 100 BD in a six-year 
period is shown in Table 2. 
The consumption of the 3rd generation 
cephalosporins (ceftriaxone and ceftazidime) was 
66.8% of all cephalosporins used in a six-year period. 
Overall consumption of cephalosporins in defined daily 
doses (DDDs) according to Anatomical Therapeutical 
Table 1. Defined daily doses [DDDs] of antibiotics according to Anatomical Therapeutic Chemical classes per 100 bed days [BD] in the 
Military Medical Academy, 2011-2016. 
Year 2011 2012 2013 2014 2015 2016 
DDDs/100 BD 42.8 39.7 46.5 43.3 46.0 33.4 
 
Table 2. The consumption of antibiotics according to the risk for patients to develop Clostridium difficile infection in defined daily doses 
[DDDs] per 100 bed days [BD] during 2011-2016. 
Classification of different antibiotics according to the 
risk of developing CDI 
Consumption in DDDs/100 BD during six years 
2011 2012 2013 2014 2015 2016 
High-risk antibiotics 
Cephalosporins 18.6 14.1 16.5 16.8 17.8 12.4 
Carbapenems 3.1 4.3 4.7 3.7 5.0 4.6 
Fluoroquinolones 2.3 1.7 1.5 2.1 1.5 0.6 
Clindamycin 0.0 0.3 0.5 0.7 0.4 0.3 
Medium-risk 
antibiotics 
Penicillins 2.5 3.0 4.0 2.6 3.3 1.0 
Aminoglycosides 4.3 5.2 5.6 4.3 5.6 4.1 
Macrolides 0.0 0.1 0.2 0.4 0.3 0.1 
Sulfametoxazole and 
Trimethoprim 
0.4 0.4 0.8 0.7 0.4 0.2 
Low-risk antibiotics Tigecycline 2.9 3.7 4.1 3.2 4.5 1.3 
 
Figure 4. Percentage of consumption of cephalosporins, 
carbapenems and aminoglycosides among overall antibiotic 
consumption in the Military Medical Academy, 2011-2016. 
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Chemical classes per 100 bed days (BD) is shown in 
Figure 5. 
On the other hand, several broad spectrum 
antibiotics had a total consumption less than 5 
DDD/100 BD during the six-year period. The 
consumption of glycopeptides (vancomycin and 
teicoplanin) was in the range of 1.3 DDD/100 BD in 
2016 to 3.0 DDD/100 BD in 2015, while teicoplanin 
use was less than 1.00 DDD/100 BD. 
Colistin consumption was at 0.1 DDD/100 BD from 
2011 to 2014, but there was an increasing trend in the 
two following years and a total consumption of 0.2 
DDD/100 BD. 
Linezolid use was recorded only during three years 
(in 2014 and 2016 it was 0.1 DDD/100 BD and in 2015 
twice that). 
Correlations between consumption of antibiotics 
classified according to the risk for patients to develop 
Clostridium difficile infection (CDI) and incidence 
density (ID) of CDI in medical and surgical patients are 
shown in Table 3. There was no statistically significant 
correlation between any groups of antibiotics. 
However, the 3rd generation cephalosporins showed 
correlation with the highest value of total consumption 




During the six-year period from 2011 to 2016, 
surveillance on HAIs was conducted in patients at the 
MMA hospital in Belgrade; antibiotic consumption was 
also measured. Like data obtained from the study 
conducted in another tertiary hospital in Serbia [18], our 
investigation showed that cephalosporins were the most 
frequently prescribed antibiotics, followed by 
aminoglycosides and carbapenems.  
Although we noticed a decrease in cephalosporin 
use in 2016, the use of the 3rd generation 
cephalosporins was constant over the study period. Our 
results are in accordance with studies from other 
countries, where cephalosporins were the most 
frequently used antibiotics in hospitals, ranging from 
30% in Chinese tertiary hospitals to 57% in Turkish 
hospitals [19-21]. Reports of antibiotic consumption in 
Table 3. Correlation between consumption of antibiotics classified according to the risk for patients to develop Clostridium difficile infection 
[CDI] and incidence density [ID] of CDI in medical and surgical patients. 
Class of Antibiotics  MedicalIDCDI Surgical IDCDI TotalIDCDI 
Cephalosporins 
Pearson Correlation -0.724 -0.092 -0.673 
Sig.[2-tailed] 0.104 0.862 0.143 
Carbapenems 
Pearson Correlation 0.083 -0.100 0.002 
Sig.[2-tailed] 0.876 0.850 0.996 
Fluoroquinolones 
Pearson Correlation -0.736 -0.112 -0.558 
Sig.[2-tailed] 0.096 0.833 0.250 
Clindamycin 
Pearson Correlation -0.472 0.008 -0.412 
Sig.[2-tailed] 0.344 0.989 0.417 
Penicillins 
Pearson Correlation -0.707 0.193 -0.413 
Sig.[2-tailed] 0.116 0.715 -0.416 
Aminoglycosides 
Pearson Correlation -0.475 0.067 -0.282 
Sig.[2-tailed] 0.341 0.900 0.589 
Macrolides 
Pearson Correlation -0.867 -0.369 -0.825 
Sig.[2-tailed] 0.025 0.472 0.043 
Sulfametoxazole and 
Trimethoprim 
Pearson Correlation -0.486 0.294 -0.095 
Sig.[2-tailed] 0.332 0.572 0.858 
Tigecyclines 
Pearson Correlation -0.225 -0.150 -0.262 
Sig.[2-tailed] 0.668 0.777 0.616 
 
Figure 5. Overall consumption of cephalosporins in defined 
daily doses (DDDs) according to Anatomical Therapeutic 
Chemical classes per 100 bed days (BD)in the Military Medical 
Academy, 2011-2016. 
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European hospitals during 2011-2015 showed that 
consumption of cephalosporins and other beta-lactams 
included carbapenems ranged from 7% in the United 
Kingdom to 54% in Bulgaria [22]. National data on 
antibacterial consumption in Australia for the five-year 
period (2012-2016) revealed the greater usage of broad 
spectrum cephalosporins (ceftriaxone, ceftazidime, 
cefepime and cefotaxime) in larger hospitals might be 
explained by a more complex casemix [23].  
During 2011, Ju et al. reported that rate of SSI was 
the highest among cases that were classified as 
dirty/infected (8.5%) and the lowest in the cases of the 
wounds that were clean (1.8%) [24], which is similar to 
our observations. Third generation cephalosporins, 
especially ceftriaxone, have generally not been 
recommended for surgical antimicrobial prophylaxis 
[25-27], but they have been widely accepted as the most 
common drugs in surgical antimicrobial prophylaxis in 
our hospital. Administration of surgical antimicrobial 
prophylaxis less than 30 minutes before incision has 
been routine practice at the MMA. The recommended 
duration of surgical antimicrobial prophylaxis is less 
than 24 hours for most procedures (except 
cardiothoracic procedures). However, in every day 
practice during clean/contaminated, contaminated and 
dirty/infected operative procedures, MMA surgeons 
extended surgical antimicrobial prophylaxis to more 
than 24 hours. The first EU-wide, ECDC-coordinated 
point prevalence survey of HAIs and antimicrobial use 
in acute care hospitals showed that surgical 
antimicrobial prophylaxis was prolonged for more than 
one day in 59.2% of cases [28]. However, the last CDC 
Guideline for the Prevention of SSI, published in 2017, 
pointed out that for clean and clean-contaminated 
procedures, additional prophylactic antimicrobial agent 
doses should not be administered after the surgical 
incision is closed in the operating room, even in the 
presence of a drain [29]. 
Decreased use of fluoroquinolones was noticed in 
2016. The most frequently used was ciprofloxacin, 
while moxifloxacin has not been used yet due to the 
limited number of standard indications. A report from 
Australia showed that fluoroquinolone use had a 
downward trend over the period 2012-2016 [23], while 
in MMA the decrease of 37% was recorded in 2016 in 
comparison to 2015. Data from nine regional tertiary 
hospitals in Ireland for 2011-2012 showed that 
fluoroquinolone use was 5.8 DDD/100 BD in 2011 and 
5.9 DDD/100 BD in the 2012 [30]. In the same period, 
the consumption of the same group in MMA was lower 
(2.3 DDD/100 BD in 2011 and 1.7 DDD/100 BD in 
2012). Consumption of fluoroquinolones in different 
European hospitals during 2011-2015 ranged from 4% 
in United Kingdom to 19% in Malta [22]. Consumption 
of fluoroquinolones in MMA during 2011-2016 varied 
from 1.7% to 5.4%. The administration of 
fluoroquinolones emerged as the most important RF for 
CDI in Quebec during one of the first described 
epidemics caused by a hypervirulent strain of 
Clostridum difficile [31]. Recently, authors from 
England reported that national fluoroquinolone and 
cephalosporin prescribing practice correlated highly 
with the incidence of CDI, in contrast to total antibiotic 
prescribing. They also concluded that restriction of 
fluoroquinolone prescribing should be a cornerstone in 
the control of epidemic CDI in the UK and worldwide 
[32].  
We did not find a correlation between 
fluoroquinolone consumption (nor any other group of 
antibiotics) and ID of CDIs. The only association 
established between ID of CDI and an individual group 
of antibiotics was with the 3rd generation cephalosporin 
in surgical patients. The overall ID of CDI was highest 
in 2016 at 4.7 per 10,000 patient-days in our hospital, 
which is lower than the mean ID of 7.0 of HA CDI 
(country range 0.7–28.7) in a European, multicentre, 
prospective, biannual point prevalence study of CDI in 
hospitalized patients with diarrhea (EUCLID) [33]. We 
also observed the differences in ID of CDI between 
medical and surgical patients. Silva-Velazco et al. 
reported that although surgical patients tended to have 
more difficult clinical presentation of CDI, overall they 
did better than medical patients. However, future 
studies focusing on modifiable RFs for each group are 
needed [34]. 
In order to improve the quality of especially broad 
spectrum antibiotic use, a multidisciplinary healthcare 
team (infectious disease specialist, epidemiologist, 
clinical pharmacologist, hospital pharmacist, clinical 
microbiologist) was formed in our hospital in 2008. The 
main goal of this team is to monitor the use of 
antibiotics and to make that more appropriate. The team 
determined the list of restricted antimicrobial agents as 
well as the criteria for their use combined with an 
approval system. In comparison to analysis of antibiotic 
consumption in the previous ten-year period (2001-
2010) in MMA, when the average consumption was 
56.6 ± 3.01 DDD/100 BD, we have noticed a 25% 
decrease in consumption of antibiotics, due to the 
efforts of the multidisciplinary team to reduce irrational 
use of antibiotics in our hospitals, especially the 
restricted ones [35].  
The highest consumption of carbapenems was 
recorded in 2015, with a total rate of 11.0%. It is not 
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surprising that in the same year the highest ID of HAI 
was observed in patients in surgical ICU and 
neurological ICU. The most frequently used was 
meropenem, which has become a key restricted-line 
antibacterial because of its superior activity against 
Pseudomonas species and lower incidence of 
neurotoxicity. 
The median consumption rate of tygecycline in our 
hospital was similar to that reported from Ireland (3.3 
DDD/100 BD in Ireland vs. 2.9 DDD/100 BD in MMA 
in the year 2011; 3.5 DDD/100 BD in Ireland vs. 3.7 
DDD/100 BD in MMA in the year 2012) [30]. Its 
current position in the context of rational antibiotic 
prescribing policy in our hospital is not yet defined. 
In MMA, colistin is an important antibacterial in the 
treatment of HAIs caused by carbapenemase-producing 
multidrug-resistant gram-negative microorganisms, 
where meropenem is ineffective. Since it was registered 
for the Serbian market in 2013, it was not often used up 
to 2014, with a slight increase in the following two 
years. This result reflects the fears of MMA doctors 
about its serious adverse effects.  
Linezolid is reserved for complex infections caused 
by multidrug resistant gram-positive organism 
including vancomycin-resistant Enteroccoci (VRE).  
Parenteral colistin, teicoplanin and linezolid usage 
remained low, but showed a possible trend upwards that 
requires ongoing monitoring. The very low usage 
teicoplanin may be due to its higher cost in comparison 
to vancomycin in Serbia. 
 
Strengths and limitations 
Our study has several limitations. First, it was a 
single-center study. The consumption of antibiotics 
may not be representative for other hospitals in the 
country. Second, we did not calculate the resistance 
ratio of microorganisms which were the cause of HAI 
during the study period. One of the limitations was the 
DDD methodology for calculating use of antibiotics in 
our research. The use of prescribed daily doses (PDDs) 
is nowadays widely used for measuring antibiotic 
consumption in hospitals because it will give the 
amount of a drug that has actually been prescribed. 
Some authors think that there are discrepancies between 
the two methods [17,36]. Obviously, additional 
research is needed to determine which method should 
be used for calculation of antibiotic usage. Finally, we 
have not taken into account the oral formulations of 
antimicrobial drugs, which will be considered in future 
investigations. 
The strength of this study is the large material 
covering the consumption of all antibiotics used in the 
MMA and the emergence of HAI in ICU, SSI and CDI 
during six years. This long surveillance period gives 
good insight into the rate of HAIs and the consumption 
of antibiotics in a tertiary care hospital in a small, poor, 
developing country with the problems resulting from 
economic transition in the healthcare system. 
 
Conclusions 
Our analysis showed that cephalosporins were the 
most frequently prescribed antibiotics, followed by 
aminoglycosides and carbapenems in a tertiary hospital 
in Belgrade, Serbia. Surgical antimicrobial prophylaxis 
is one reason for the high consumption of 
cephalosporins in MMA. The multidisciplinary 
healthcare team had very important role in monitoring 
of the use of antibiotics and would have crucial 
importance in the implementation of the antibiotic 
stewardship program in order to decrease unnecessary 
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